The biotech capital markets remained active with sizable listings and fresh financing aimed at advancing clinical programs and platform buildout. Attovia extended the sector’s IPO streak with a $289 million offering for three immunology and inflammation drug candidates. In parallel, Twist Bioscience priced a $300 million public offering, with net proceeds planned for R&D, manufacturing capacity expansion and additional product development. These moves reflect continued investor appetite for late preclinical through commercial-adjacent platforms even as clinical readouts remain uneven across major therapeutic areas. For operators, the funding provides runway for clinical data generation and scale—both essential in a biotech environment where trials and regulatory pathways directly drive valuation.